TY - JOUR
T1 - What is the oncologic risk of stem cell treatment for heart disease?
AU - Hatzistergos, Konstantinos E.
AU - Blum, Arnon
AU - Ince, Tan
AU - Grichnik, James M.
AU - Hare, Joshua M.
PY - 2011/5/27
Y1 - 2011/5/27
N2 - Accumulating clinical and preclinical trials are adding to the database, supporting the idea that human cell therapy with MSC transplantation is a safe and a reliable procedure for treating heart disease. Long-term rigorous patient monitoring demonstrates the durability and safety of cell-based therapies for heart disease, with no incidence of tumorigenesis. As with any new therapy, extreme vigilance is required to monitor for, manage, and understand the risk of unwanted and desirable side effects. The specter of neoplasia raises major concerns. However, we conclude that the observations in rodent animal models used to study human diseases should be interpreted with caution when assessing safety and efficacy of any new therapeutic modality and that the risk- benefit profile of MSC cell therapy in the rodent is substantially different from that in large mammals. We believe that ongoing trials of MSCs in humans are of acceptable risk, but strongly argue for ongoing vigilance, particularly over the long term.
AB - Accumulating clinical and preclinical trials are adding to the database, supporting the idea that human cell therapy with MSC transplantation is a safe and a reliable procedure for treating heart disease. Long-term rigorous patient monitoring demonstrates the durability and safety of cell-based therapies for heart disease, with no incidence of tumorigenesis. As with any new therapy, extreme vigilance is required to monitor for, manage, and understand the risk of unwanted and desirable side effects. The specter of neoplasia raises major concerns. However, we conclude that the observations in rodent animal models used to study human diseases should be interpreted with caution when assessing safety and efficacy of any new therapeutic modality and that the risk- benefit profile of MSC cell therapy in the rodent is substantially different from that in large mammals. We believe that ongoing trials of MSCs in humans are of acceptable risk, but strongly argue for ongoing vigilance, particularly over the long term.
UR - http://www.scopus.com/inward/record.url?scp=79958090499&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79958090499&partnerID=8YFLogxK
U2 - 10.1161/CIRCRESAHA.111.246611
DO - 10.1161/CIRCRESAHA.111.246611
M3 - Article
C2 - 21617132
AN - SCOPUS:79958090499
SN - 0009-7330
VL - 108
SP - 1300
EP - 1303
JO - Circulation Research
JF - Circulation Research
IS - 11
ER -